Percutaneous computed tomography-guided cryoablation in the lung: a single institution series

Evgenia Efthymiou, Ornella Moschovaki Zeiger, Nikolaos Achilleas Arkoudis, Stylianos Argentos, Alexis Kelekis, Nikolaos Kelekis, Dimitrios Filippiadis


Purpose: The purpose of the present study is to report a single center’s experience and to evaluate the efficacy and safety of Computed Tomography (CT)-guided cryoablation (CA) for the treatment of primary and metastatic lung lesions.

Material and Methods: Institutional database research from 01/04/2019 till 01/04/2020 identified 8 patients with primary or secondary lung lesions (n=15) who were treated by CT-guided CA and were evaluable for the 6 months follow-up. Technical and clinical success on a per tumour and per patient basis as well as complication rates were recorded. Neoplasmatic substrate included non-small-cell lung carcinoma (NSCLC) (n=2) and metastases from sarcoma (n=3), pancreatic (n=1) and colon (n=2) carcinoma. Mean patient age was 64.3 years (range 23-80 years) and male/female ratio was 5/3.

Results: Median size of the lesions was 1 cm (range 0.4-2.5 cm). Median number of tumours was 1.87 (range 1-4). The mean procedure time was 66.92 min (range 50-84 min), including local anaesthesia, cryoprobe(s) placement, ablation and postprocedural CT evaluation. Median length of hospital stay was 2.5 days (range 1-8 days). Local recurrence-free response (local tumour efficacy) of the treated lesions at 6 months was 93.33% (14/15) and 100% following a second cryoablation treatment for recurrent tumour. The rate of pneumothorax requiring pleural catheter placement was 25% (2/8). Additionally there were 3 grade 2 complication events during 13 procedures.

Conclusions: The present study demonstrates that percutaneous CT-guided CA constitutes a safe and effective ablation technique for primary and metastatic lung lesions.


Lung; Cryoablation; Bronchogenic carcinoma; Metastasis

Full Text:



Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1-21.

Herold CJ, Bankier AA, Fleischmann D. Lung metastases. Eur Radiol 1996; 6: 596-606.

Welch BT, Brinjikji W, Schmit GD, et al. A national analysis of the complications, cost, and mortality of percutaneous lung ablation. J Vasc Interv Radiol 2015; 26(6): 787-791.

Lam A, Yoshida EJ, Bui K, et al. A National Cancer Database analysis of radiofrequency ablation versus stereotactic body radiotherapy in early-stage Non-Small Cell Lung Cancer. J Vasc Interv Radiol 2018; 29(9): 1211-1217.e1.

Venturini M, Cariati M, Marra P, et al. CIRSE Standards of Practice on thermal ablation of primary and secondary lung tumours. Cardiovasc Intervent Radiol 2020; 43(5): 667-683.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422.

Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). J Thorac Oncol 2020; pii: S1556-0864(20)30188-X.

Dupuy DE, Zagoria RJ, Akerley W, et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol 2000; 174(1): 57-59.

Vogl TJ, Naguib NN, Lehnert T, et al. Radiofrequency, microwave and laser ablation of pulmonary neoplasms: clinical studies and technical considerations--review article. Eur J Radiol 2011; 77(2): 346-357.

de Baère T, Aupérin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015; 26(5): 987-991.

de Baere T, Tselikas L, Gravel G, et al. Lung ablation: Best practice/results/response assessment/role alongside other ablative therapies. Clin Radiol 2017; 72(8): 657-664.

Georgiades CS, Marx JK. Cryoablation: mechanism of action and devices. In: Hong K, Georgiades CS (eds). Percutaneous tumor ablation strategies and techniques. Thieme 2011; pp 15-26.

Hinshaw JL, Littrup PJ, Durick N, et al. Optimizing the protocol for pulmonary cryoablation: a comparison of a dual- and triple-freeze protocol. Cardiovasc Intervent Radiol 2010; 33(6): 1180-1185.

Lyons GR, Askin G, Pua BB. Clinical outcomes after pulmonary cryoablation with the use of a triple freeze protocol. Vasc Interv Radiol 2018; 29(5): 714-721.

Filippiadis DK, Binkert C, Pellerin O, et al. Cirse quality assurance document and standards for classification of complications: The cirse classification system. Cardiovasc Intervent Radiol 2017; 40(8): 1141-1146.

Eiken PW, Welch BT. Cryoablation of lung metastases: Review of recent literature and ablation technique. Semin Intervent Radiol 2019; 36(4): 319-325.

Palussière J, Catena V, Lagarde P, et al. Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option? Int J Hyperthermia 2019; 36(2): 46-52.

Prud'homme C, Deschamps F, Moulin B, et al. Image-guided lung metastasis ablation: a literature review. Int J Hyperthermia 2019; 36(2): 37-45.

de Baere T, Tselikas L, Woodrum D, et al. Evaluating cryoablation of metastatic lung tumors in Patients-Safety and Efficacy: The ECLIPSE Trial-Interim Analysis at 1 year. J Thorac Oncol 2015; 10(10): 1468-1474.

Macchi M, Belfiore MP, Floridi C, et al. Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial. Med Oncol 2017; 34(5): 96.

Moussa AM, Ziv E, Solomon SB, et al. Microwave ablation in primary lung malignancies. Semin Intervent Radiol 2019; 36(4): 326-333.

Kurilova I, Gonzalez-Aguirre A, Beets-Tan RG, et al. CT. Microwave ablation in the management of colorectal cancer pulmonary metastases. Cardiovasc Intervent Radiol 2018; 41(10): 1530-1544.

Das SK, Huang YY, Li B et al. Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non-small cell lung cancer. Oncol Lett 2020; 19(1): 1031-1041.

Jiang B, Mcclure MA, Chen T, et al. Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis. Ann Thorac Med 2018; 13(4): 243-250.

Littrup PJ, Jallad B, Vorugu V, et al. Lethal isotherms of cryoablation in a phantom study: Effects of heat load, probe size and number. J Vasc Interv Radiol 2009; 20(10): 1343-1351.

Kennedy SA, Milovanovic L, Dao D, et al. Risk factors for pneumothorax complicating radiofrequency ablation for lung malignancy: a systematic review and metaanalysis. J Vasc Interv Radiol 2014; 25: 1671-1681.



  • There are currently no refbacks.